Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.
Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.
复制标题
DOI：
10.1557/mrc.2017.85
复制
发表时间：
2017-09
影响因子：
1.9
通讯作者：
Harley BAC
中科院分区：
文献类型：
--
作者：
Pedron S;Polishetty H;Pritchard AM;Mahadik BP;Sarkaria JN;Harley BAC
虽然临床前模型，如从患者来源的标本在小鼠中产生的原位肿瘤被广泛用于预测癌症的敏感性或治疗干预，但这种异种移植可能是缓慢的，需要广泛的基础设施，并且可能使原位评估变得困难。在高度侵袭性的癌症中，如胶质母细胞瘤（GBM），这种担忧加剧，显示遗传多样性和短平均生存期。仿生生物材料技术提供了一种创建反映肿瘤微环境（TME）生物物理特征的离体模型的方法。我们描述了一种微流控模板方法来产生含有患者来源的GBM细胞的空间梯度水凝胶，以探索药物疗效和耐药机制。
While preclinical models such as orthotopic tumors generated in mice from patient-derived specimens are widely used to predict sensitivity or therapeutic interventions for cancer, such xenografts can be slow, require extensive infrastructure, and can make in situ assessment difficult. Such concerns are heightened in highly aggressive cancers, such as glioblastoma (GBM), that display genetic diversity and short mean survival. Biomimetic biomaterial technologies offer an approach to create ex vivo models that reflect biophysical features of the tumor microenvironment (TME). We describe a microfluidic templating approach to generate spatially graded hydrogels containing patient-derived GBM cells to explore drug efficacy and resistance mechanisms.